Clinical trials: Untreated
Chronic Myeloid Leukemia
STI571 ProspectIve RandomIzed Trial: SPIRIT
To test whether increasing the dose of imatinib or combining it with IFNalpha or ara-C increases the rate of molecular response (as measured by the decrease in BCR-ABL transcripts after 12 months of treatment) in patients with…
- Trial name
- SPIRIT (NCT00219739)
- Testing
- Imatinib mesylate 400 mg, Imatinib mesylate 600 mg, Imatinib 400 mg + Peg-Interferon
- Where
- France
- Volunteers
- 789 people
- Sponsor
- Poitiers University Hospital
T Cell Non-Hodgkin's Lymphoma
Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma
The purpose of this study is to determine determine the maximum tolerated dose (MTD) and safety of the combination of Chidamide combined with CHOEP(cyclophosphamide， epirubicin,vindesine, etoposide and prednisone) regimen as…
- Trial name
- NCT02987244
- Testing
- Chidamide, Cyclophosphamide, Epirubicin
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Non-Hodgkin's Lymphoma (NHL)
Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)
The primary objective of the study is to determine the efficacy, as measured by overall response (complete response + partial response) of bendamustine in combination with ofatumumab in previously untreated patients with indolent…
- Trial name
- NCT01108341
- Testing
- Bendamustine hydrochloride, Ofatumumab
- Where
- 39 sites in United States, Belgium and 1 more
- Volunteers
- 50 people
- Sponsor
- Cephalon
Hypertension
Oral Cannabidiol Effect on Blood Pressure in Hypertensive Patients
The objective of this randomized, placebo-controlled and crossover study is to extend the findings from the acute studies into more chronic administration of CBD in individuals with mild or moderate hypertension who are either…
- Trial name
- HYPER-H21-4 (NCT05346562)
- Testing
- Cannabidiol
- Where
- Croatia
- Volunteers
- 70 people
- Sponsor
- University of Split, School of Medicine
Fear of Spiders, Fear of Heights
Generalized Fear Extinction to Untreated Fear Stimuli in Specific Phobias After Exposure
This study investigates whether a one-session exposure treatment for spider-related stimuli can lead to a generalization of extinguished fear to height-related stimuli in individuals with comorbid fear of spiders and fear of…
- Trial name
- NCT03907345
- Testing
- Exposure
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Ruhr University of Bochum
Lung Cancer
Paclitaxel Plus Radiation Therapy in Treating Patients With Untreated Stage III Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells.
- Trial name
- NCT00002519
- Testing
- chemotherapy, paclitaxel, radiation therapy
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Chronic Kidney Disease
A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia
The objective of this study is to evaluate the efficacy and the safety when ASP1517 is intermittently administered in Erythropoiesis Stimulating Agent (ESA)-untreated non-dialysis chronic kidney disease patients with anemia.
- Trial name
- NCT02964936
- Testing
- roxadustat
- Where
- 38 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Astellas Pharma Inc
Extensive-Stage Small-Cell Lung Cancer
Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer
The purpose of this study is to determine the maximum tolerated dose and assess the safety, tolerability and activity of carfilzomib given in combination with carboplatin and etoposide as initial therapy for patients with…
- Trial name
- NCT01987232
- Testing
- Carfilzomib, Carboplatin, Etoposide
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 32 people
- Sponsor
- Amgen
Parkinson's Disease (PD)
A Phase 2 Study to Assess the Effects of SUL-238 on High Energy Phosphates With ³¹P-MRS in Patients With Early, Untreated Parkinson's Disease
The main goal of the study is to investigate how well the new drug SUL-238 works in Parkinson's Disease (PD). This is done by means of an MRS scan. An MRS scan is similar to a regular MRI scan.
- Trial name
- SHEPHERD (NCT07322887)
- Testing
- SUL-238 (1500 mg t.i.d.) film-coated tablets, SUL-238 (500 mg t.i.d.) film-coated tablets
- Where
- Netherlands
- Volunteers
- 45 people
- Sponsor
- GEN İlaç ve Sağlık Ürünleri A.Ş.
Non Squamous Non Small Cell Lung Cancer
Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer
This randomized phase II study will compare the efficacy and safety of the combination of carboplatin and pemetrexed with and without OGX-427 in patients with previously untreated advanced non-squamous NSCLC.
- Trial name
- Spruce (NCT01829113)
- Testing
- OGX-427
- Where
- 16 sites in United States
- Volunteers
- 155 people
- Sponsor
- SCRI Development Innovations, LLC
Non Squamous Lung Cancer
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung
This study will evaluate the anti-cancer effects of crizotinib when compared with standard chemotherapy in patients with ALK positive lung cancer.
- Trial name
- PROFILE 1014 (NCT01154140)
- Testing
- treatment
- Where
- 249 sites in United States, Australia and 29 more
- Volunteers
- 343 people
- Sponsor
- Pfizer
Metastatic Biliary Tract Cancer, Metastatic Biliary Tract Carcinoma
Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer
Based on preclinical data from the Lim lab (WUSM), the investigators hypothesize that IRAK4 inhibition cripples tumor-intrinsic survival signaling and effectively overcomes the desmoplastic and immune-suppressive tumor…
- Trial name
- NCT07107750
- Testing
- Emavusertib, Gemcitabine, Cisplatin
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Washington University School of Medicine
Acute Biphenotypic Leukemia, de Novo Myelodysplastic Syndrome
Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
This phase I/II trial studies the side effects and best dose of mitoxantrone hydrochloride when given together with filgrastim, cladribine, and cytarabine and to see how well they work in treating patients with acute myeloid…
- Conditions
- Acute Biphenotypic Leukemia, de Novo Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia
- Trial name
- NCT02044796
- Testing
- Cladribine, Cytarabine, Filgrastim
- Where
- United States
- Volunteers
- 199 people
- Sponsor
- Fred Hutchinson Cancer Center
B-Cell Chronic Lymphocytic Leukemia
A Study to Evaluate the Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL)
This is a multi-center, open-label, single arm Phase 1/2 study evaluating the feasibility, safety, and tolerability of a series of 16 immunizations of Id-KLH with GM-CSF in patients with previously untreated B-CLL.
- Trial name
- NCT00302861
- Testing
- MyVax
- Volunteers
- 86 people
- Sponsor
- Genitope Corporation
Sarcoma
Biomarkers in Samples From Young Patients With Soft Tissue Sarcoma
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT01342783
- Testing
- DNA analysis, RNA analysis, mutation analysis
- Volunteers
- 20 people
- Sponsor
- Children's Oncology Group
Lymphoma, B-Cell
Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma
The purpose of this study is to determine whether using high-dose chemotherapy, monoclonal antibodies, and targeted radioimmunotherapy will slow the progression of disease in patients with high-risk Non-Hodgkin's Lymphoma (NHL).
- Trial name
- NCT00577629
- Testing
- cyclophosphamide, etoposide, rituximab
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Duke University
Parkinson Disease
Compensation Mechanisms in Parkinson's Disease
Parkinson's disease onset is clinically defined as the appearance of motor symptoms including akinesia, tremor and hypertonia. Several studies have shown that motor symptoms occur when at least 50 % of dopaminergic neurons are…
- Trial name
- DATACOMT (NCT02869945)
- Testing
- Identification of COMT HH, COMT HL or COMT LL genes, Brain MRI with resting state scan, Brain MPET
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Non-Hodgkin's Lymphoma
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE)
This was a prospective, open-label, Phase III, multicenter, single-arm trial designed to assess the safety, pharmacokinetics, and pharmacodynamics of an alternative dosing rate of rituximab in previously untreated patients with…
- Trial name
- RATE (NCT00719472)
- Testing
- Rituximab, CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone), CVP (cyclophosphamide, vincristine, prednisone)
- Volunteers
- 451 people
- Sponsor
- Genentech, Inc.
Stage IV Small Cell Lung Cancer
A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy
The study consists of a Phase1b lead-in portion to determine the maximum tolerated dose (MTD) of OMP-59R5 (tarextumab) in combination with etoposide (EP) for 6 cycles followed a Phase 2, multi center, randomized…
- Trial name
- PINNACLE (NCT01859741)
- Testing
- OMP-59R5, Etoposide, Cisplatin or Carboplatin
- Where
- 35 sites in United States
- Volunteers
- 172 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Brain and Central Nervous System Tumors
Radiation Therapy Plus Carboplatin and Lobradimil in Treating Children With Newly Diagnosed Brain Stem Gliomas
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as carboplatin and lobradimil may make the tumor cells more sensitive to radiation therapy.
- Trial name
- NCT00005602
- Testing
- carboplatin, cereport, radiation therapy
- Where
- 19 sites in United States
- Volunteers
- 13 people
- Sponsor
- Children's Oncology Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.